Kantar Health is hosting an Oncology Conference Insight seminar on 17 September 2014 in Madrid, Spain, for pharmaceutical companies. The seminar will highlight the recent drug approvals and treatment trends, pricing and reimbursement implications, and clinical results on the oncology competitive landscape. The seminar will also offer an opportunity for a candid, mutual exchange of opinions and ideas. Additionally, we are incorporating qualitative input from community oncologists to further validate thoughts on the future of clinical development.
Richard Wagner, Ph.D.
Vice President, Kantar Health
- Breast Cancer
Discussion of recent data and market impact associated with development in hormone
receptor-positive breast cancer
A review of pivotal new data for BRAF inhibitors and PD-1/PD-L1 inhibitors and a discussion of the future evolution of treatment in this disease
- Non-Small Cell Lung Cancer (NSCLC)
A discussion of recent developments in relapsed/refractory disease (Cyramza, necitumumab, pembrolizumab) and next-generation inhibitors in biomarker subpopulations (EGFR, ALK)
Discussion of new data for PD-1/PD-L1 inhibitors and other immunotherapeutics in development, with a review of development strategies
- Chronic Lymphocytic Leukemia
Discussion of recent pivotal data (Imbruvica, idelalisib, Arzerra, Gazyva) and the rapidly changing standard of care in this disease
for more information and to download the registration form. Note: The presentation will start at 10:00 am. We will allow for Q&A following the presentations. This event will be followed by a networking event with refreshments.